Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells (original) (raw)
- Brief Communication
- Published: 29 April 1998
Gene Therapy volume 5, pages 419–426 (1998)Cite this article
- 278 Accesses
- 22 Citations
- 3 Altmetric
- Metrics details
Abstract
Ganciclovir (GCV) and its lipophilic elaidic acid ester prodrug E-GCV were evaluated for their antiherpetic, cytostatic and metabolic properties. E-GCV proved exquisitely inhibitory to the replication of herpes simplex virus type 1 (HSV-1) and HSV-2 in cell cultures (50% effective concentration (EC50): 0.002 μM). It was five- to 10-fold more effective than its parent drug GCV. E-GCV was at least 2000-fold more cytostatic to HSV-1 or HSV-2 thymidine kinase (tk) gene-transfected mammary carcinoma FM3A tk−/HSVtk+ tumor cells than to the corresponding nontransfected tumor cells. The cytostatic activity of E-GCV to the HSVtk gene-transfected tumor cells was far superior to that of GCV. Metabolic studies revealed that both GCV and E-GCV were converted to the mono-, di- and tri-phosphate derivatives of GCV to a markedly higher extent in FM3Atk−/HSV-1 tk+ cells than in wild- type FM3A/0 cells. Strikingly, mono-, di- and tri-phosphate metabolites of GCV were retained for a substantially longer time in E-GCV-treated cells (half-life approximately 50 h) than in GCV-treated cells (half-life approximately 20 h). The longer retention time of the GCV metabolites most likely explains why E-GCV is superior to GCV against herpes simplex virus replication and HSVtk gene-transfected tumor cell proliferation. Taking into account the marked stability of E-GCV in human plasma and its much higher lipophilicity than GCV, E-GCV should be considered as an effective lipophilic prodrug of GCV with a markedly enhanced cytostatic activity in HSVtk gene-transfected tumor cells compared with parental ganciclovir. Its usefulness in the combined gene/chemotherapy of HSVtk gene-transfected tumors should be further pursued.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
J Balzarini, B Degrève, G Andrei, J Neyts & E de Clercq - Norsk Hydro, Porsgrunn, Norway
M Sandvold & F Myhren
Authors
- J Balzarini
You can also search for this author inPubMed Google Scholar - B Degrève
You can also search for this author inPubMed Google Scholar - G Andrei
You can also search for this author inPubMed Google Scholar - J Neyts
You can also search for this author inPubMed Google Scholar - M Sandvold
You can also search for this author inPubMed Google Scholar - F Myhren
You can also search for this author inPubMed Google Scholar - E de Clercq
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Balzarini, J., Degrève, B., Andrei, G. et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.Gene Ther 5, 419–426 (1998). https://doi.org/10.1038/sj.gt.3300586
- Received: 17 July 1997
- Accepted: 27 October 1997
- Published: 29 April 1998
- Issue Date: 01 March 1998
- DOI: https://doi.org/10.1038/sj.gt.3300586